SPRO — Spero Therapeutics Share Price
0.000.00%
Last trade - 00:00- $75.45m
- -$0.88m
- $103.78m
- 36
- 98
- 93
- 89
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.71 | ||
| Price to Tang. Book | 0.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.73 | ||
| EV to EBITDA | -0.04 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.79% | ||
| Return on Equity | 24.95% | ||
| Operating Margin | 20.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 18.15 | 9.33 | 18.26 | 53.51 | 103.78 | 48.23 | 47.83 | 92.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206. The tebipenem HBr is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. SPR206 is a direct acting intravenous (IV)-administered product candidate being developed as an option to treat MDR Gram-negative bacterial infections in the hospital setting.
Directors
- Milind Deshpande NEC (64)
- Ankit Mahadevia PRE (40)
- Satyavrat Shukla CFO (49)
- Cristina Larkin COO (50)
- Tamara Joseph OTH (58)
- Timothy Keutzer OTH (53)
- David Melnick OTH (69)
- Scott Jackson IND (56)
- John Pottage IND (68)
- Cynthia Smith IND (52)
- Frank Thomas IND (51)
- Kathleen Tregoning IND (50)
- Patrick Vink IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 12th, 2013
- Public Since
- November 2nd, 2017
- No. of Shareholders
- 8
- No. of Employees
- 46
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 53,892,889
- Address
- 675 Massachusetts Ave Ste 14, CAMBRIDGE, 02139-3309
- Web
- https://sperotherapeutics.com/
- Phone
- +1 8572421600
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for SPRO
Q2 2024 Spero Therapeutics Inc Earnings Release
Spero Therapeutics Inc Annual Shareholders Meeting
Similar to SPRO
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Spero Therapeutics share price?
As of Today at 19:20 UTC, shares in Spero Therapeutics are trading at $1.40. This share price information is delayed by 15 minutes.
How has the Spero Therapeutics share price performed this year?
Shares in Spero Therapeutics last closed at $1.40 and the price had moved by -16.67% over the past 365 days. In terms of relative price strength the Spero Therapeutics share price has underperformed the S&P500 Index by -30.65% over the past year.
What are the analyst and broker recommendations for Spero Therapeutics?
The overall consensus recommendation for Spero Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Spero Therapeutics dividend yield?
Spero Therapeutics does not currently pay a dividend.
Does Spero Therapeutics pay a dividend?
Spero Therapeutics does not currently pay a dividend.
When does Spero Therapeutics next pay dividends?
Spero Therapeutics does not currently pay a dividend.
How do I buy Spero Therapeutics shares?
To buy shares in Spero Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Spero Therapeutics?
As of the previous close price of $1.40, shares in Spero Therapeutics had a market capitalisation of $75.45m.
Where are Spero Therapeutics shares listed?
Here are the trading details for Spero Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SPRO
What kind of share is Spero Therapeutics?
Based on an overall assessment of its quality, value and momentum Spero Therapeutics is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Spero Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Spero Therapeutics is $7.50. That is 435.71% above the last closing price of $1.40.
Analysts covering Spero Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.94 for the next financial year.
What is the trend in the Spero Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Spero Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +11.08%.
As of the last closing price of $1.40, shares in Spero Therapeutics were trading +0.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Spero Therapeutics PE Ratio?
The Spero Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Spero Therapeutics?
Spero Therapeutics' management team is headed by:
- Milind Deshpande - NEC
- Ankit Mahadevia - PRE
- Satyavrat Shukla - CFO
- Cristina Larkin - COO
- Tamara Joseph - OTH
- Timothy Keutzer - OTH
- David Melnick - OTH
- Scott Jackson - IND
- John Pottage - IND
- Cynthia Smith - IND
- Frank Thomas - IND
- Kathleen Tregoning - IND
- Patrick Vink - IND